HomeComparePCHUY vs PFE

PCHUY vs PFE: Dividend Comparison 2026

PCHUY yields 1.13% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.7K in total portfolio value· pulled ahead in Year 8
10 years
PCHUY
PCHUY
● Live price
1.13%
Share price
$4.88
Annual div
$0.06
5Y div CAGR
-46.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.9K
Annual income
$0.22
Full PCHUY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PCHUY vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCHUYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCHUY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PCHUY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCHUY
Annual income on $10K today (after 15% tax)
$96.31/yr
After 10yr DRIP, annual income (after tax)
$0.19/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCHUY + PFE for your $10,000?

PCHUY: 50%PFE: 50%
100% PFE50/50100% PCHUY
Portfolio after 10yr
$34.7K
Annual income
$13,129.47/yr
Blended yield
37.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PCHUY
No analyst data
Altman Z
1.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCHUY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCHUYPFE
Forward yield1.13%6.13%
Annual dividend / share$0.06$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-46.5%13.2%
Portfolio after 10y$19.9K$49.6K
Annual income after 10y$0.22$26,258.71
Total dividends collected$131.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PCHUY vs PFE ($10,000, DRIP)

YearPCHUY PortfolioPCHUY Income/yrPFE PortfolioPFE Income/yrGap
1$10,761$60.62$9,153$693.39+$1.6KPCHUY
2$11,546$32.61$8,593$849.25+$3.0KPCHUY
3$12,372$17.50$8,336$1,066.78+$4.0KPCHUY
4$13,248$9.37$8,437$1,384.80+$4.8KPCHUY
5$14,180$5.02$9,013$1,875.40+$5.2KPCHUY
6$15,175$2.69$10,306$2,680.72+$4.9KPCHUY
7$16,239$1.44$12,820$4,101.38+$3.4KPCHUY
8← crossover$17,377$0.77$17,673$6,826.70$296.00PFE
9$18,593$0.41$27,543$12,591.86$8.9KPFE
10$19,895$0.22$49,560$26,258.71$29.7KPFE

PCHUY vs PFE: Complete Analysis 2026

PCHUYStock

PTT Public Company Limited, together with its subsidiaries, operates as a petroleum and petrochemical company in Thailand, other Asian countries, Europe, the United States, and internationally. It operates through Upstream Petroleum and Natural Gas Business Group, Downstream Petroleum Business Group, and New Business and Infrastructure Group. The company is involved in the exploration and production of petroleum; and natural gas procurement, pipeline transmission, distribution, and separation activities. In addition, it engages in the exploration, production, and distribution of coal; and marketing of petroleum products and lube oil through an operating system of procurement, storage, and distribution of products, as well as the retail business at service stations. Further, the company imports and exports petroleum and petrochemical products, as well as other related products; produces and distributes electricity, steam, and water for industrial purpose; and offers project management, human resource support, petroleum related technology, consultant management, technical consultant for electricity businesses, petrol station and convenience store management, factory maintenance and engineering, oil and gas, safety and environmental, and business services, as well as services for the storage and handling of liquid chemicals. Additionally, it invests in liquefied natural gas business; produces and distributes chilled water/constructs and installs electricity generating systems; develops electricity power production projects; develops, markets, and distributes polymers products, by products, and other polymers-related products; develops real estate properties; operates vocational schools; and manufactures and distributes biochemical products, paraxylene, and industrial coatings and additives, as well as engages in the transportation, warehouse, and bagging packing management of polyethylene. The company was founded in 1978 and is headquartered in Bangkok, Thailand.

Full PCHUY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PCHUY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCHUY vs SCHDPCHUY vs JEPIPCHUY vs OPCHUY vs KOPCHUY vs MAINPCHUY vs JNJPCHUY vs MRKPCHUY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.